Her2

Edit

HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs ...

GetNews 21 Mar 2026

It covers the HER2 Positive Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products ... HER2 Positive Gastric Cancer Overview ... Cancers with increased levels of HER2 are called HER2-positive.

Edit

HER2-Positive Breast Cancer Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering ...

GetNews 21 Mar 2026

Patients with PIK3CA-mutant HR-/HER2+ and HR+/HER2+ breast cancer may enroll, the latter cohort will receive concomitant treatment with standard doses of fulvestrant to block HR signaling ... HER2 Positive Breast Cancer Overview.

Edit

HER2-Negative Breast Cancer Clinical Pipeline Witnesses Significant Growth as 70+ Companies Accelerate Therapeutic Innovation | DelveInsight

GetNews 20 Mar 2026

"HER2-Negative Breast Cancer Clinical Trials" ... Access DelveInsight’s detailed HER2-Negative Breast Cancer Pipeline Report here. ... HER2-Negative Breast Cancer ... Emerging Drug Profiles in HER2-Negative Breast Cancer.

Edit

Biotheryx Announces First Patient Dosed in the Dose Expansion Phase of BTX-9341-101 for the Treatment of HR+/HER2- Breast Cancer

PR Newswire 18 Mar 2026

BTX-9341 is a first-in-class, oral degrader of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer ... in second line HR+/HER2- metastatic breast cancer.

Edit

HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively ...

GetNews 18 Mar 2026

DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape.

Edit

HR Positive/ HER2 Negative Breast Cancer Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation ...

GetNews 17 Mar 2026

DelveInsight’s, “HR Positive/ HER2 Negative Breast Cancer Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape.

Edit

HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | ...

GetNews 12 Mar 2026

"HER2-Negative Metastatic Breast Cancer Market" ... To explore detailed insights related to market outlook, therapy adoption, treatment patterns, and epidemiology trends, visit the HER2-Negative Metastatic Breast Cancer Market Forecast @.

Edit

OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting

The Daily Record - Dunn 11 Mar 2026

FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS ....

Edit

FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer: A Market-Shaping Milestone ...

GetNews 10 Mar 2026

"FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer" ... What does ENHERTU's approval mean for competing HER2-directed therapies in your pipeline? Download .

Edit

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (Celcuity Inc)

Public Technologies 10 Mar 2026

For most treatment-na¨ıve patients with hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer (ABC), combination therapy with an endocrine agent and a ...

Edit

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive ...

Caledonian Record 09 Mar 2026

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Mar 9, 2026-- ....

Edit

ENHERTU� Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive ...

Business Wire 09 Mar 2026

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer ... .

Edit

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer (Daiichi Sankyo Co Ltd)

Public Technologies 09 Mar 2026

as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU ...

Edit

Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer (AstraZeneca plc)

Public Technologies 09 Mar 2026

With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer, and are exploring its potential in ...

Edit

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer (AstraZeneca Pharmaceuticals LP)

Public Technologies 09 Mar 2026

HER2-Positive, HER2-Low, and HER2-Ultralow Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg) ... HER2-Positive, HER2-Low, and HER2-Ultralow Metastatic Breast ...

Podcasts:

Latest News for: her2

HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs ...

HER2-Positive Breast Cancer Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering ...

HER2-Negative Breast Cancer Clinical Pipeline Witnesses Significant Growth as 70+ Companies Accelerate Therapeutic Innovation | DelveInsight

Biotheryx Announces First Patient Dosed in the Dose Expansion Phase of BTX-9341-101 for the Treatment of HR+/HER2- Breast Cancer

HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively ...

HR Positive/ HER2 Negative Breast Cancer Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation ...

HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | ...

OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting

FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer: A Market-Shaping Milestone ...

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (Celcuity Inc)

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive ...

ENHERTU� Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive ...

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer (Daiichi Sankyo Co Ltd)

Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer (AstraZeneca plc)

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer (AstraZeneca Pharmaceuticals LP)

Article Search

EXPLORE WN.com